Login / Signup

Mycobacterium tuberculosis inhibits METTL14-mediated m 6 A methylation of Nox2 mRNA and suppresses anti-TB immunity.

Mingtong MaYongjia DuanCheng PengYou WuXinning ZhangBoran ChangFei WangHua YangRuijuan ZhengHongyu ChengYuanna ChengYifan HeJingping HuangJinming LeiHanyu MaLiru LiJie WangXiaochen HuangFen TangJun LiuJinsong LiRuoyan YingPeng WangWei ShaYawei GaoLin WangBaoxue Ge
Published in: Cell discovery (2024)
Internal N 6 -methyladenosine (m 6 A) modifications are among the most abundant modifications of messenger RNA, playing a critical role in diverse biological and pathological processes. However, the functional role and regulatory mechanism of m 6 A modifications in the immune response to Mycobacterium tuberculosis infection remains unknown. Here, we report that methyltransferase-like 14 (METTL14)-dependent m 6 A methylation of NAPDH oxidase 2 (Nox2) mRNA was crucial for the host immune defense against M. tuberculosis infection and that M. tuberculosis-secreted antigen EsxB (Rv3874) inhibited METTL14-dependent m 6 A methylation of Nox2 mRNA. Mechanistically, EsxB interacted with p38 MAP kinase and disrupted the association of TAB1 with p38, thus inhibiting the TAB1-mediated autophosphorylation of p38. Interaction of EsxB with p38 also impeded the binding of p38 with METTL14, thereby inhibiting the p38-mediated phosphorylation of METTL14 at Thr72. Inhibition of p38 by EsxB restrained liquid-liquid phase separation (LLPS) of METTL14 and its subsequent interaction with METTL3, preventing the m 6 A modification of Nox2 mRNA and its association with the m 6 A-binding protein IGF2BP1 to destabilize Nox2 mRNA, reduce ROS levels, and increase intracellular survival of M. tuberculosis. Moreover, deletion or mutation of the phosphorylation site on METTL14 impaired the inhibition of ROS level by EsxB and increased bacterial burden or histological damage in the lungs during infection in mice. These findings identify a previously unknown mechanism that M. tuberculosis employs to suppress host immunity, providing insights that may empower the development of effective immunomodulators that target M. tuberculosis.
Keyphrases